ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1406

Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study

Jesús T. Sánchez-Costa1, Rafael B. Melero-González2, Elisa Fernández-Fernández3, María T. Silva-Diaz4, Joaquín M. Belzunegui5, Clara Moriano6, Julio Sánchez7, Judit Lluch8, Itziar Calvo9, Vicente Aldasoro10, Lydia Abasolo11, Javier Loricera12, Alberto Ruíz-Román13, Santos Castañeda14, Patricia Moya15, María J. Garcia-Villanueva16, Vanessa A. Navarro-Angeles17, Carles Galisteo18, Anne Riveros-Frutos19, Jose A. Román-Ivorra20, Selene Labrada-Arrabal21, Margarida Vasques-Rocha22, Carlota L. Iñiguez-Ubiaga23, María García-González24, Clara Molina-Almela25, María Alcalde-Villar26, Antonio Juan Mas27, Eugenio De Miguel28, Javier Narvaez29, Miguel Ángel gonzalez-Gay30, Noemí Garrido-Puñal13, Paula V. Estrada-Alarcon17 and Ricardo Blanco31, 1Research unit, Spanish Society of Rheumatology, Madrid, Spain, 2Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 3Rheumatology department, La Paz University Hospital, Madrid, Spain, 4Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, 5Hospital Universitario Donostia, Donostia-San Sebasti, Spain, 6Hospital Universitario de León, León, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, 9Basurto University Hospital, Bilbao, Spain, 10Complejo Hospitalario de Navarra, Pamplona, Spain, 11Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, 12Hospital Universitario Marqués de Valdecilla, Santander, Spain, 13Hospital Universitario Virgen del Rocío, Sevilla, Spain, 14Hospital Universitario de la Princesa, Madrid, Spain, 15Hospital Sant Pau, Barcelona, Spain, 16Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, 17Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, 18Hospital Universitari Parc Tauli, Saadell, Spain, 19Hospital Germans Trias i Pujol, Badalona, Spain, 20Hospital Universitari i Politècnic La Fe, Valencia, Spain, 21Hospital del Mar, Barcelona, Spain, 22Hospital Universitario Araba, Vitoria-Gasteiz, Spain, 23Hospital Universitario Lucus Augusti, Lugo, Spain, 24Hospital Universitario de Canarias, La Laguna, Spain, 25Rheumatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain, 26Hospital Universitario Severo Ochoa, Leganés, Spain, 27Rheumatology Department, Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 28Hospital Universitario La Paz, Madrid, Spain, 29Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 30Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 31Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Epidemiology, giant cell arteritis, longitudinal studies, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Epidemiological information on Giant Cell Arteritis (GCA) comes mainly from the Scandinavian countries of northern Europe, which show a higher incidence than the countries of southern Europe. GCA clinical manifestations can be divided into cranial, extracranial, and general syndrome.

In a large series of GCA from Spain, we studied a) the incidence of GCA, b) clinical manifestations, and c) comorbidities at the time of disease diagnosis.

Methods: ARTESER is a retrospective epidemiological observational study of GCA promoted by the Spanish Society of Rheumatology in which 26 hospitals participate. The inclusion criteria were: all new patients diagnosed with GCA by a) ACR criteria, b) positive diagnostic test (temporal artery biopsy, temporal artery ultrasound or other relevant imaging techniques) and/or c) investigator’s clinical judgment. The patient recruitment period ranged from June 1, 2013 to March 29, 2019. The overall incidence of GCA per 100,000 people ≥50 years for the whole period and the mean annual incidence were evaluated. The clinical variables were collected by reviewing the patient’s medical history.

Results: 1675 patients were included. The average annual incidence rate was 7.42 (95% CI: 6.57-8.27). All the cases were older than 50 years, and the age group with the highest incidence was that of 80 to 84 years, where it reached a value of 130.12 (95% CI: 126.71-133.54). The mean annual incidence is higher in women than in men 10.06 (95% CI: 8.7-11.5) vs 4.83 (95% CI 3.8- 5.9) (Table 1).

The description of the population is shown in Table 2, the mean age at diagnosis was 76.9±8.1 years, 1178 (70.3%) were women. ACR criteria were met by 1400 (83.6%) patients and an objective diagnostic test by 1258 (75.1%). The more frequent comorbidity was arterial hypertension (n=1079; 64.6%), followed by dyslipidemia (n=801, 48%). The predominant cranial manifestation was headache, (n= 1337; 79.9%) and 605 patients experienced visual symptoms (36.1%). Polymyalgia rheumatica (n=699; 41.8%) and asthenia (n=837; 52.2%) were the most frequent extracranial and general syndrome manifestation, respectively. Regarding laboratory parameters, the most characteristic data was the increase of ESR (75.9±33.6 mm/1st h).

Conclusion: The mean annual incidence of GCA in Spain, 7.42 (95% CI: 6.57-8.27), is lower than that of the Scandinavian countries. It is higher in people older than 80 years. Cranial manifestations constituted the most clinical features. The most frequent clinical manifestations are cranial. Up to a third of patients had visual manifestations.

Table 1. Incidence rate by age groups and sex from June 2013 to March 2019 (x 100,000 inhabitants ≥50 years)

Table 2. General characteristics, comorbidities and clinical manifestations


Disclosures: J. Sánchez-Costa, None; R. Melero-González, None; E. Fernández-Fernández, None; M. Silva-Diaz, None; J. Belzunegui, None; C. Moriano, None; J. Sánchez, None; J. Lluch, None; I. Calvo, None; V. Aldasoro, None; L. Abasolo, None; J. Loricera, None; A. Ruíz-Román, None; S. Castañeda, None; P. Moya, None; M. Garcia-Villanueva, None; V. Navarro-Angeles, None; C. Galisteo, None; A. Riveros-Frutos, None; J. Román-Ivorra, None; S. Labrada-Arrabal, None; M. Vasques-Rocha, None; C. Iñiguez-Ubiaga, None; M. García-González, None; C. Molina-Almela, None; M. Alcalde-Villar, Nordic, 12, Tutor of rheumatology trainee at regional congress; A. Juan Mas, None; E. De Miguel, Roche, 6, 12, Paid instructor, Abbvie, 2, 5, 6, Novartis, 2, 5, 6, 12, Paid instructor, Pfizer, 2, 5, 6, MSD, 6, BMS, 6, UCB, 6, Grunental, 6, Janssen, 6, 12, Paid instructor, Sanofi, 6, Galapagos, 2; J. Narvaez, None; M. gonzalez-Gay, None; N. Garrido-Puñal, None; P. Estrada-Alarcon, None; R. Blanco, Brystol Myers Squibb, 6.

To cite this abstract in AMA style:

Sánchez-Costa J, Melero-González R, Fernández-Fernández E, Silva-Diaz M, Belzunegui J, Moriano C, Sánchez J, Lluch J, Calvo I, Aldasoro V, Abasolo L, Loricera J, Ruíz-Román A, Castañeda S, Moya P, Garcia-Villanueva M, Navarro-Angeles V, Galisteo C, Riveros-Frutos A, Román-Ivorra J, Labrada-Arrabal S, Vasques-Rocha M, Iñiguez-Ubiaga C, García-González M, Molina-Almela C, Alcalde-Villar M, Juan Mas A, De Miguel E, Narvaez J, gonzalez-Gay M, Garrido-Puñal N, Estrada-Alarcon P, Blanco R. Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/incidence-and-general-clinical-features-of-giant-cell-arteritis-in-the-arteser-multicenter-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-general-clinical-features-of-giant-cell-arteritis-in-the-arteser-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology